Dysregulation of RNA Splicing in Tauopathies

Authors
Daniel J. Apicco, Cheng Zhang, Brandon Maziuk, ..., Choong Ung, Hu Li, Benjamin Wolozin

Correspondence
li.hu@mayo.edu (H.L.), bwolozin@bu.edu (B.W.)

In Brief
RNA binding proteins are emerging as drivers of neurodegeneration. Apicco et al. show a dysregulation of RNA splicing in mouse and human tauopathies, with partial correction by reducing TIA1. A systems analysis suggests novel approaches for the therapy of tauopathy.

Highlights
- Transcripts encoding spliceosomal and mRNA binding proteins are reduced in PS19 brain
- Alternative splicing in PS19 brain favors transcripts encoding synaptic proteins
- TIA1 regulates the expression of Xist and sexually dimorphic genes
- Inhibition of MYC and EGFR protects against tau-mediated toxicity
## INTRODUCTION

Microtubule associated protein tau (MAPT or tau) normally binds microtubules to stabilize the axonal cytoskeleton. In a collection of neurological disorders termed tauopathies, tau becomes misfolded and aggregates into insoluble inclusions termed neurofibrillary tangles (NFTs) (Zempel and Mandelkow, 2014). Despite being the defining pathological hallmark of tauopathy, little is understood about the potential pathological functions and mechanisms of mis-sorted tau. Our group recently discovered that somatodendritic tau co-localizes with TIA1, an RBP with an intrinsically disordered region (IDR, also referred to as a low-complexity or prion-like domain) that functions as a core nucleating SG protein, which stimulates the regulated aggregation of additional RBPs in the cytoplasm (Anderson and Keder-sha, 2008; Vanderweyde et al., 2012, 2016). The role of somatodendritic tau in the biology of RBPs also suggested that RBPs might reciprocally regulate the pathophysiology of tau. Pursuing this hypothesis, we recently demonstrated that reduction of TIA1 in the PS19 P301S tau mouse model results in a delay of neurodegeneration, protection against behavioral deficits and a prolongation of lifespan (Apicco et al., 2018). Further, these mice exhibited reduced nuclear-to-cyttoplasmic translocation of TIA1, reduced formation of cytoplasmic RNA granules containing markers of SGs, and increased stabilization of microtubules (Apicco et al., 2018). The disease modifying effects of TIA1 reduction, the colocalization of TIA1 with somatodendritic tau, and the effects of somatodendritic tau on SG accumulation raise the possibility that dysfunction of RNA metabolism might be an important contributor to the pathophysiology of tauopathy.

Here, we assessed whether tauopathies are associated with deficits in RNA metabolism. Our results demonstrate a significant dysfunction of RNA splicing in both the PS19 tau mouse model and in the Alzheimer disease (AD) brain. Importantly, we also show that reduced expression of TIA1 in PS19 mice normalizes some of the disease-related changes in RNA splicing. We then used an unbiased systems biology approach to identify upstream regulators that might contribute to the transcriptional and splice variant changes in the neuroprotected PS19 Tia1+/− mice compared to the PS19 Tia1+/+ tauopathy mice. We identify several targets, including MYC and the EGFR receptor (EGFR), that drive the pathological changes in both PS19 mice and primary neuronal cultures. This work suggests that dysregulated splicing is an important pathophysiological mechanism in tauopathies and identifies therapeutic approaches for disease modification.

## RESULTS

### RNA Metabolic Processes Are Dysregulated in PS19 Tauopathy Mice

In order to determine how the RNA transcriptome is altered in PS19 tauopathy mice, we isolated total RNA extracts from the cortex of 9-month-old wild-type (WT), PS19 (P301S Tia1+/−) and P301S Tia1+/+ mice (refer to the STAR Methods for a...
We first used next-generation RNA sequencing (RNA-seq) to analyze the differential expression of mRNA levels in PS19 compared to WT mice. 339 genes were discovered to be significantly up- or downregulated (FDR < 0.05) in the PS19 cortex compared to WT mice. These genes showed significant negative enrichment (downregulation) (Table S2), including pre-mRNA splicing (false discovery rate [FDR] = 2.7E–4), processing of capped intron-containing pre-mRNA (FDR = 5.4E–4), and mRNA-splicing (FDR = 6.6E–4). Further, the topmost significant downregulated GO biological process and cellular component terms were RNA splicing (FDR = 1.10E–2) and spliceosomal complex (FDR = 1.1E–3), respectively (Table S2). In contrast, no pathway gene sets were positively enriched with statistical significance, suggesting that there is not a strong biological trend in the genes that become upregulated in tauopathy. Analysis of the downregulated pathways in the PS19 compared to non-transgenic mice suggests that abnormal processing of mRNA, especially RNA splicing, is one of the predominant features of tauopathy (Figure 1A; Table S2).

We next examined whether the downregulation of pathways related to RNA metabolism reflected an underlying reduction in the expression level of mRNA-encoding spliceosomal proteins and RBPs. Expression-level analysis was performed for mRNA data that were encompassed by the GO molecular function annotation “RNA-binding” (Figure 1B). Of the 37 RBPs transcripts identified, 30 were decreased in the PS19 compared to the WT samples (Figure 1B), including Snrnp70, Rbm 11/17, Hnrnpa3, Snrp b/c/f, and U2af1, which indicates a strong response of RBP biology in the PS19 mouse brain. About 25% of these proteins (10/37) participate in spliceosomal function, including Snrpn 70, b/c/f, U2af1, LSM2, 10, Safb2, Prpf3, and Srm1.

Since previous results in Drosophila melanogaster demonstrated striking re-expression of transposable elements in response to the TDP-43-mediated degenerative process (Lj et al., 2013), we also examined the expression of transposons in the PS19 model. Transcripts mapping to multiple different genetic locations were identified and quantified in our RNA-seq data. No transposable elements exhibited significant differences in expression in PS19 compared to WT mice (Figure 1C). Combined, these data suggest that the genetic dysregulation caused by tauopathy is selective to particular pathways and that a reduction of RNA-splicing processes is particularly notable.

**Alternative Splicing of Genes Encoding Synaptic Proteins Is Disrupted in PS19 Mice**

The observation that RNA-splicing pathways are downregulated in PS19 mice led us to investigate the specific mRNAs that were subject to alternative splicing. Thus, we further analyzed our RNA-seq data using the Olengo and Quantas programs to identify significant alternative splicing events in the PS19 compared to WT brain (Wu et al., 2013). Olengo detects six different types of alternative splicing events: cassette exons (skipped exon), tandem cassettes (exon duplication), mutually exclusive exons (mutually exclusive inclusion of one of two alternative exons), alternative 5’ splice site selection, alternative 3’ splice site selection, and intron retention. Cassette exons were by far the most observed event in our RNA-seq data, constituting 58.6% of detected events, followed by tandem cassettes (13.9%), intron retention (13.0%), alternative 3’
or 5’ splice site selection (8.6%), and mutually exclusive exons (4.9%). We then analyzed the list of alternatively spliced mRNA transcripts using the DAVID bioinformatics tool (Huang da et al., 2009) in order to describe the biological functions of alternatively spliced genes, and to gain insight into the cellular functions affected by abnormal splicing in tauopathies. Analysis of the list of genes exhibiting statistically significant (FDR-adjusted p values < 0.05) splice variants in PS19 compared to WT brain revealed an enrichment in bioinformatic terms related to synaptic neurotransmission. The top 10 most significant GO biological process annotation terms included synapse (FDR = 6.23E-14), presynaptic membrane (FDR = 2.06E-10), postsynaptic density (FDR = 6.42E-8), and dendrite (FDR = 3.83E-6) (Figure 2A; Table S4). These data suggest that a number of RNA transcripts involved in neurotransmission and synaptic structure/function are subjected to aberrant splicing induced by tauopathy.

We next investigated the specific splice isoforms and exons most significantly affected in PS19 mice (Figures 2B and 2C). Figure 2B summarizes the top 20 most significant alternative splicing events detected in PS19 compared to the WT cortex. Notably, 10 of these 20 transcripts encode proteins with known roles at the synapse (bold). Note that some genes appear on the list multiple times because a change in mutually exclusive exons will also be recorded as a significant cassette (exon skipping) event, etc. Please refer to Tables S3 and S6 for the complete list of alternative splicing results.

(C) Hierarchically clustered heatmap of exon inclusion indices for alternatively spliced cassette exons in RNA-seq of 9-month PS19 Tia1+/+, PS19 Tia1+/−, Tia1−/−, and WT cortex. Inclusion indices for statistically significant (FDR < 0.1) cassette exon alternative splicing (AS) events were calculated by dividing the number of reads including a given exon where an inclusion/skip occurs by the total number of reads for that transcript. Z-transformed inclusion indices were then plotted in a heatmap to visualize changes in exon inclusion between genotypes. Genes were hierarchically clustered according to GO analysis (box inset, below). Note that Tia1 reduction in PS19 mice (P301S tau Tia1+/−, green) returns the majority of transgenic tau-induced changes in PS19 mice (P301S Tau Tia1+/+, red) toward WT levels, particularly in the nervous system development (light green), presynaptic process (dark red), and synaptic signaling (orange) GO clusters. Blue to red color scale denotes negative to positive Z scores (color key, right).

**Figure 2. mRNA Transcripts Encoding Synaptic Proteins Are Alternatively Spliced in PS19 Brain**

(A) For PS19 versus WT frontal cortex, top 10 most statistically significant Gene Ontology (GO) biological process annotation terms enriched (FDR < 0.05) in the gene list of mRNA transcripts exhibiting significant changes in splicing, as determined by OLoge and Quantas splice variant analysis. (B) Top 20 most statistically significant individual splice variants in PS19 compared to WT cortex. Note that 11 of the top 20 alternatively spliced transcripts encode proteins with known functional roles at the synapse (bold). Note that some genes appear on the list multiple times because a change in mutually exclusive exons will also be recorded as a significant cassette (exon skipping) event, etc. Please refer to Tables S3 and S6 for the complete list of alternative splicing results. (C) Hierarchically clustered heatmap of exon inclusion indices for alternatively spliced cassette exons in RNA-seq of 9-month PS19 Tia1+/+, PS19 Tia1+/−, Tia1−/−, and WT cortex. Inclusion indices for statistically significant (FDR < 0.1) cassette exon alternative splicing (AS) events were calculated by dividing the number of reads including a given exon where an inclusion/skip occurs by the total number of reads for that transcript. Z-transformed inclusion indices were then plotted in a heatmap to visualize changes in exon inclusion between genotypes. Genes were hierarchically clustered according to GO analysis (box inset, below). Note that Tia1 reduction in PS19 mice (P301S tau Tia1+/−, green) returns the majority of transgenic tau-induced changes in PS19 mice (P301S Tau Tia1+/+, red) toward WT levels, particularly in the nervous system development (light green), presynaptic process (dark red), and synaptic signaling (orange) GO clusters. Blue to red color scale denotes negative to positive Z scores (color key, right).

Gria2 is elevated almost 2-fold in PS19 compared to the WT cortex (Table S3), producing an increase in Flip GluR2-containing AMPA receptors—a process that causes AMPA receptors to desensitize more slowly, rendering the cell more susceptible to excitotoxicity (Koike et al., 2000; Pei et al., 2009). The RNA-seq data also identified alterations in two other critical synaptic genes with known roles in synaptic transmission, demonstrating that both Snap25 and Camk2b are alternatively spliced in the PS19 cortex (Figure 2B; Table S3). Performing qPCR on RNA extracted from fresh sets of tissue demonstrated the validity of the changes observed in the PS19 samples (Figures 3A–3C). Taken together, the high prevalence in PS19 mice of dysfunctional RNA splicing in genes encoding proteins involved in glutamatergic synaptic transmission suggests that dysregulation of this system could be an important contributor to memory deficits in tauopathies.

**TIA1 Reduction Partially Rescues Dysfunctional Synaptic Splicing in PS19 Mice**

Our previous work had shown that reducing TIA1 expression in the PS19 mouse model led to a decreased tau-mediated SG response, reduced tau oligomer accumulation, and increased the lifespan in these mice (Apicco et al., 2018). Given the current identification of a global dysfunction in RNA splicing in PS19 mice and the role of TIA1 in RNA metabolism, we investigated whether TIA1 reduction might also affect alternative splicing.
First, we analyzed whether the 174 genes detected as significant cassette splice variants in our PS19 versus WT mice also exhibited TIA1 binding signatures by comparing our RNA-seq data to previously published TIA1 data from individual nucleotide resolution ultraviolet crosslinking and immunoprecipitation experiments (iCLIP) (Wang et al., 2010). We observed that 49 out of the 174 genes (28.2%, \( p = 0.019 \)) exhibited TIA1 binding peaks in the iCLIP analysis, suggesting that TIA1 dysfunction partially contributes to the splicing defects in PS19 mice (Table S3, second tab).

We proceeded to compare the relative levels of alternative splice isoforms of mRNA transcripts in P301S Tia1\(^{+/+}\) mice with those in P301S Tia1\(^{-/-}\) mice. GO analysis of alternatively spliced transcripts in P301S Tia1\(^{+/+}\) compared to the P301S Tia1\(^{-/-}\) cortex revealed that the top-three most significant annotation terms are synapse (FDR = 3.86E\(-12\)), postsynaptic density (FDR = 4.33E\(-12\)), and presynaptic membrane (FDR = 1.14E\(-10\)) (Table S5). While indicating a clear effect on splicing, this result could not distinguish between an increased dysregulation of (i.e., exacerbation) and a decrease in (i.e., rescue) splicing changes relative to WT mice. We therefore examined the inclusion indices for all cassette exon splicing events detected between all four genotypes to determine how TIA1 reduction of (i.e., exacerbation) and a decrease in (i.e., rescue) splicing changes relative to WT mice. We therefore examined the inclusion indices for all cassette exon splicing events detected between all four genotypes to determine how TIA1 reduction partially contributes to the splicing defects in PS19 mice (Table S3, second tab).

We next investigated whether TIA1 reduction corrected the splicing alterations in the specific excitatory synaptic transcripts most significantly changed in PS19 compared to the non-transgenic cortex (Figure 2B), including Gria2, Snap25, and Camk2b. We designed primer pairs that spanned exon junctions of transcripts including or excluding the affected exons, as well as primers to amplify total transcript levels (spanning constitutive exons) for normalization of each splice isoform (Figures 3A–3C). Real-time PCR analysis of cortex tissues collected from new 6-month-old mice (n = technical duplicates of 6 mice/group; 3 males and 3 females per group) confirmed that the ratios of exon inclusion were statistically different in PS19 compared to the WT cortex for all three transcripts (Figures 3A–3C); these results are similar to those reported recently by Hsieh et al. (2019). More importantly, TIA1 reduction restored the ratio of exon inclusion versus exclusion toward the levels detected in WT mice for some transcripts despite there being no overt change in neurodegenerative phenotype (Figure 2C). This result suggests that TIA1 acts to shift the splicing of some transcripts relevant to neurodegeneration in a manner that is independent of the presence of overt neurodegeneration.

We also compared transcriptional profiles of P301S Tia1\(^{+/+}\) and P301S Tia1\(^{-/-}\) mice (Figures S1 and S2; Table S1). The results showed a large number of genes whose transcriptional profiles were changed by Tia1 haplo-insufficiency (Table S6b). However, the FDR-adjusted p values for the top 10 most significant
GO annotation terms revealed did not produce as strong enrichment values as observed for the splicing changes (Table S7).

**TIA1 Heterozygosity Regulates Expression of Sexually Dimorphic Genes**

The RNA-seq data also revealed a surprising role for TIA1 in regulating sexually dimorphic genes. Analysis of the transcriptomes in WT and $Tia1^{+/−}$ mice showed modest changes ($≤50\%$) in expression for 928 genes, but dramatic regulation of the long non-coding RNA (lncRNA) Xist, and four genes on the Y chromosome normally silenced by Xist. The top 5 differentially expressed transcripts all encode sexually dimorphic proteins, including Ddx3y (FDR = 6.24E $−09$), Uty (FDR = 3.62E $−12$), Xist (FDR = 3.32E $−09$), Ef2s3y (FDR = 1.09E $−16$), and Kdm5d (FDR = 2.99E $−20$) (Table S8). Transcripts expressed on the Y chromosome (Ddx3y, Uty, Ef2s3y, and Kdm5d) were significantly reduced in $Tia1^{+/−}$ compared to the WT cortex, while levels of transcripts expressed from the X chromosome such as Xist were significantly elevated (Figure S2A). Independent analysis of mRNA transcript levels in new 6-month-old mice ($n = 6$/group) and 3 males and 3 females per genotype confirmed that $Tia1$ heterozygosity significantly increased expression of Xist and reduced expression of Ddx3y, Uty, Ef2s3y, and Kdm5d in males (Figure S2B). Xist was increased in female $Tia1^{−/−}$ mice by 83% ($p = 0.019$). Levels of Ddx3y, Uty, Ef2s3y, and Kdm5d were undetectable in females, as expected. Xist does not normally regulate genes on the Y chromosome. The responsiveness of these genes might reflect the higher levels of Xist expression in the $Tia1^{−/−}$ mouse because previous studies have shown that elevated levels of Xist expression can lead to mislocalization of Xist binding (Pageau et al., 2007). In the case of our studies, we hypothesize that the reduced expression of Ddx3y, Uty, Ef2s3y, and Kdm5d results either from reduced transcriptional stimulation by TIA1, or from increased silencing due to increased Xist expression and concomitant “off target” repression of genes that share strong homology with the normal targets of Xist expression.

**An Unbiased Systems-Level Analysis Identifies Targets Driving Neurodegeneration in Tauopathy**

Our transcriptomic analyses indicate that the behavioral protection from tauopathy in P301S $Tia1^{−/−}$ mice is associated with a reversion to normal splicing of synaptic mRNAs (Figure 3). We next focused on the global, network-level changes underlying the aberrant transcriptional and splicing events detected in the RNA-seq, with the intention to discover biological targets capable of regulating the protective effects of TIA1 reduction. We used the NetDecoder algorithm previously developed by da Rocha et al. (2016) to systematically query the brain mRNA transcriptome of WT, P301S $Tia1^{−/−}$, and P301S $Tia1^{−/−}$ mice. NetDecoder is a network biology platform capable of reconstructing context-specific network profiles in terms of context-dependent information flow profiles using pairwise phenotypic comparative analyses (da Rocha et al., 2016). Here, information means the preference of flow mediated by protein-protein interactions due to shared biological functions, where the preference of information flow is determined by gene expression levels as well as coexpression coefficients of interacting proteins in a network. NetDecoder can therefore identify molecular interaction pathways to produce an unbiased and predictive “prioritized network” that mediates the differential information flows between WT, P301S $Tia1^{−/−}$, and P301S $Tia1^{−/−}$ mice, which thereby suggest biological targets for therapeutic intervention. A more detailed description of the NetDecoder algorithm is provided in the STAR Methods section.

NetDecoder analysis of the mRNA transcriptome of the WT, P301S $Tia1^{−/−}$, and P301S $Tia1^{−/−}$ cortex identified a prioritized network with various upstream network routers, downstream targets, and key genes (Figures 5A and S3). These key genes are not necessarily differentially expressed or alternatively spliced in the PS19 mice, but their functional importance is predicted to either regulate or be affected by the aberrant mRNA expression or splicing events. Many of the genes identified were already identified by NetDecoder as key genes in human AD versus age-matched control brain tissues, including APP, UBC, MYC, PARK2, MDM2, HDACs, TARDBP, RELA, HSP90, FYN, UBE2, and SUMO subunits, among others (Figures 5 and S3) (da Rocha et al., 2016). We prioritized network from the transcriptome of the P301S $Tia1^{−/−}$ versus P301S $Tia1^{−/−}$ cortex successfully identified network routers and targets already known to regulate tau pathophysiology, such as the tau kinase FYN, the chaperone HSP90, and the E3 ubiquitin ligase STUB1/CHIP (Figure 5A), confirming the validity of this approach. More importantly, we also identified various routers, high-impact genes, and key target genes not previously associated with tau toxicity, including the proto-oncogene/transcription factor MYC and EGFR (Figures 5A–5C). Both of these proteins (MYC and EGFR) exhibited increased information flow in PS19 versus WT mice (Figure S3) and decreased information flow in the P301S $Tia1^{−/−}$ compared to the P301S $Tia1^{−/−}$ cortex (Figure 5B, blue). If these targets play...
a biologically important role, we hypothesized that inhibition of these proteins (which should mimic the decreased information flow exhibited in the P301S Tia1+/−/C0 cortex) would be protective against tau-mediated neurodegeneration.

To investigate whether the genes highlighted by our prioritized network biology approach might mediate the neuroprotective effects in the P301S Tia1+/−/C0 cortex, we proceeded to test whether functional reduction of these genes independent of TIA1 knockdown might also provide neuroprotection from SG-mediated toxicity. To do so, we assessed the effects of pharmacological inhibition of MYC, UBE2I, and EGFR on cell viability in primary mouse hippocampal neurons transduced with WT tau or vector

---

**Figure 5. Disease Phenotype in Neuroprotected PS19 Mice Is Regulated by a Prioritized Biological Network**

NetDecoder analysis was performed on the RNA-seq data from 9-month PS19 Tia1+/− and P301S Tia1+/− cortex in order to identify context-dependent changes inherent to the disease phenotype, as described previously (da Rocha et al., 2016).

(A) Prioritized network consisting of biological pathways predicted to regulate the differences in phenotype between P301S Tia1+/− (protected) and PS19 Tia1+/− (taupathy) mice. Red and blue nodes denote proteins exhibiting either increased (red) or decreased (blue) information flow in P301S Tia1+/− compared to PS19 Tia1+/− cortex. Arrows denote direction of information flow from source genes to target genes based on known protein-protein interaction (PPI) data. Network routers (diamonds) are upstream of intermediary (circles) and target (square) protein nodes.

(B–D) Key genes (B), network routers (C), and key targets (D) identified by NetDecoder analysis to mediate context-dependent disease phenotype.

(E) Selected protein-protein interactions (edges) showing differences in information flows between Tia1+/− and Tia1+/− contexts.
control adeno-associated viruses (AAVs). Pharmacological inhibition of the SUMO-conjugating enzyme UBE2I was included because it demonstrated decreased information flow in P301S Tia1+/− versus P301S Tia1+/+ mice, but not PS19 versus WT mice, and thereby served as a useful comparison for distinguishing tauopathy versus TIA1-specific effects. After 19 days in culture, neurons were treated with either vehicle control (DMSO, Veh) or chemical inhibitors to MYC (10058-F4, 5 μM), UBE2I (2-D08, 5 μM), or EGFR (TAG1478, 5 μM). After 30 min, the neurons were then treated for 1 h with sodium arsenite (125 μM) to induce SGs via the translational stress response, and toxicity was examined using both XTT and caspase 3 cleavage assays (Figures 6A–6C). Pharmacological inhibition of either MYC or EGFR indeed protected against toxicity in tau-overexpressing cultures, while inhibition of UBE2I provided no protection (Figures 6A and S3; similar results observed with both toxicity assays). MYC, EGFR, and UBE2I inhibition did not induce cell death in the absence of tau overexpression, as determined by the XTT and caspase cleavage assays (Figures 6A and S3). Although the predominant cell type in our primary hippocampal cultures are excitatory glutamatergic neurons, these cultures also contain glia, including astrocytes; thus, the neuroprotection mechanism underlying MYC and EGFR inhibition may occur in either the neurons or glia, or modulate the paracrine or physical interactions between both cell types. The effects of MYC (10058-F4, 1 or 10 μM), UBE2I (2-D08, 1 or 10 μM), or EGFR (TAG1478, 1 or 10 μM) inhibition on levels of TIA1 in SH-SY5Y cells were also examined by immunocytochemistry (Figures 6D and 6E). Pharmacological inhibition of MYC (1 μM only), EGFR, or UBE2I prevented increases in TIA1 associated with arsenite treatment (Figures 6D and 6E); the differential response of the MYC inhibitor 10058-F4 (active at 1 μM, inactive at 10 μM) might reflect a U-shaped response curve or off-target effects of the inhibitor at higher concentrations. Taken together, these results validate that many of the key genes detected in our unbiased systems biology NetDecoder analysis also regulate SG-mediated toxicity and RBP biology in primary cultured neurons, highlighting potential targets for therapeutic intervention.

**Comparison to Human AD Cases Suggests Overlapping Dysfunction in RNA Splicing**

Many of the genes identified in our NetDecoder analysis were also previously identified as being key genes in human
neurodegenerative diseases, including APP, PARK2, HTT, TARDBP, G3BP1, UBC, SETX, FYN, RELA, TP53, HDACs, UBE2I, and SUMO, among others (Ahn et al., 2009; Chen et al., 2004; Fernández-Nogales et al., 2014; Klein et al., 2000; Selkoe and Schenk, 2003; Um et al., 2012). These NetDecoder-identified key genes are those that exhibit significant changes in information flow in the whole biological network in the context of PS19 tauopathy, presumably due to aberrant RBP-mediated transcriptional or splicing events. Our NetDecoder analysis therefore suggested that there might be a common mechanistic link between the splicing defects observed in PS19 tauopathy and AD. We therefore investigated whether the defects observed in our PS19 tauopathy model might exhibit key overlap with the splicing defects observed in human AD. To probe whether the RNA-splicing changes we observed in the PS19 tau mouse brain showed a similar enrichment of neuronal genes in the AD brain, we downloaded data from the short read archive project SRP034831 of eight control and nine AD brain samples (Scheckel et al., 2016). Analysis of global splicing patterns in AD versus control brains showed large differences in splicing (Table S9; Figures 4A and 4B), confirming and extending suggestions from past work. Interestingly, analysis of the top 10 GO categories in AD samples showed some key points of overlap to those observed with the PS19 versus WT mice, with a prominence of neuronal (e.g., axon initial segment and nodes of Ranvier) and vesicular categories (e.g., endolysosomal lumen, lysosomal lumen, and phagolysosome) (Figure 2A versus Figure 4A).

Analysis of the 211 genes showing significant cassette splice variants in the AD versus healthy control brain samples indicated that 72 out of the 211 genes (34.1%, p = 7.5E–06) exhibited TIA1 binding peaks in the iCLIP results (using comparisons to existing TIA1 iCLIP data) (Table S9, last tab) (Wang et al., 2010). We also specifically examined the presence of TIA1 binding sites for the 20 genes shared in common between the mouse (PS19 versus WT) and human (AD versus Control) datasets (Wang et al., 2010). We found that 11 out of the 20 genes exhibited TIA1 binding sites (FDR 8.2E–04, APP, CLASP2, CSNK1A1, DLG2, DNM1L, DTNA, LIMCH1, MORF4L2, OXR1, RPS24, and TTC3).

There were, however, clear distinctions between the datasets, potentially reflecting the different disease stages of the human versus mouse data (end stage post-mortem samples for human versus moderate disease for the mouse samples) and the differences between AD, a secondary tauopathy, versus our mouse model of primary tauopathy. The shared components are cogent, however, suggesting that the pathophysiology of AD and the PS19 tau mouse share an overall pattern of dysfunctional RNA splicing (Figure 4B), at least partly mediated by TIA1. This result also highlights the potential for therapeutic approaches targeting RBP aggregation and RNA metabolism in both primary tauopathies and secondary tauopathies such as AD.

**DISCUSSION**

Our understanding of the pathophysiology of motor neuron disorders, including amyotrophic lateral sclerosis (ALS), has been revolutionized by major discoveries linking dysfunction of RBPs and RNA metabolism to the disease process. Mutations in RBPs and pathological accumulation of RBP aggregates are associated with ALS, frontotemporal dementia (FTD), and myopathies (Couthouis et al., 2011, 2014; Hackman et al., 2013; Kwiatkowski et al., 2009; Neumann et al., 2006, 2009; Taylor et al., 2016; Vance et al., 2009; Mackenzie et al., 2017; Yuan et al., 2018). Although most tau is associated with axonal tubulin, in diseases such as AD, tau accumulates in the somatodendritic arbor. Recent evidence indicates that somatodendritic tau functions in part to regulate SG accumulation and the translational stress response (Brunello et al., 2016; Meier et al., 2016; Vanderweyde et al., 2016). The discovery that the association of tau with RNA promotes liquid-liquid phase separation (LLPS) provides a biophysical mechanism that links the physiological process governing formation of SGs and other membrane-less organelles with the pathophysiological process producing tau aggregation and neurodegeneration (Feric et al., 2016; Li et al., 2012). The work presented above demonstrates that modulation of RBP aggregation by TIA1 reduction partially rescues the dysregulation of RNA splicing that is associated with tauopathy in PS19 mice.

Transposon expression showed no significant differences in our sample sets, which highlights the selectivity of the dysfunctional RNA metabolic processes in specific neurodegenerative diseases (for example, transposon expression in ALS and mRNA splicing in tauopathies). Our results differ from a recent report by Guo et al. (2018), which concluded that transposon activation occurs in AD. The difference in our conclusions lies in the statistical analysis. The Salmon tool used by Guo et al. assumes that the expression of total transposable elements is proportional to the total transcriptome size. However, in situations where transcriptional expression in one sample differs greatly from another sample (such as being lower), the algorithm artificially “stretches” the transposon element expression for the smaller sample up to the scale of the other sample, which makes some transposable elements appear to be artificially elevated. Therefore, we applied the Salmon algorithm after correcting for differences in the number of transposable element reads and confirmed that our data did not identify any transposons that exhibit statistically different levels of expression in our samples. These results demonstrate that the dysregulation of RNA metabolism in PS19 mice is specific to changes in mRNA transcription and alternative splicing, and suggests that aberrant mRNA splicing occurs in tauopathies much like it does in other diseases associated with RBP mutations or aggregation (Prudencio et al., 2015). More importantly, the results from this study and others place tauopathy in the continuum of diseases associated with dysfunction of RBPs.

Our analyses also showed similar trends in splicing dysfunction in the PS19 mice and human AD brain. 70% of the genes that show differential splicing in both PS19 mice and human AD brain also exhibit either genetic linkage to AD (15%) (Kohli et al., 2016; Rosenberg et al., 2016) or demonstrable involvement in disease processes (55%) (Finelli et al., 2015; Fujioka et al., 2013; Gamir-Morralla et al., 2017; Hanger et al., 2007; López-Menéndez et al., 2013). Prior studies have demonstrated dysregulation of RNA splicing in ALS, a neurodegenerative movement disorder that shows strong genetic associations with mutations in RBPs (Prudencio et al., 2015). The importance of our results is further supported by a prior study documenting splicing...
dysfunction in AD brains (Bai et al., 2013; Barbash et al., 2017), as well as work that specifically examined the function of ELAV proteins (such as HuR) and observed a similarly strong dysfunction of RNA splicing (Scheckel et al., 2016). Our study extends beyond those past findings by also examining GSEA, highlighting the prominence of spliced transcripts important for neuronal/synaptic activity in the AD brain.

The striking role of RNA-splicing dysfunction in the pathophysiology of tauopathies opens avenues for potential therapeutic intervention. The spliceosome complex utilizes RBPs and is regulated at the level of post-translational modifications of RBPs, as well as direct modifications to RNA and DNA. Many of the RBPs associated with the spliceosome aggregate in AD and mouse models of tauopathy, some co-localizing with tau inclusions, such as TIA1, and others forming independent inclusions, such as TDP-43, U1-70K, and G3BP1 (Amador-Ortiz et al., 2007; Arai et al., 2009; Bai et al., 2013; Bigio et al., 2010; Vanderweyde et al., 2012, 2016). We recently demonstrated that TIA1 reduction protects against the neurodegeneration associated with tauopathy (Apicco et al., 2018; Vanderweyde et al., 2016). We now demonstrate that this protection is associated with a corresponding rescue of aberrant RNA splicing. While the relative contributions of direct TIA1 function, differential RBP expression, and altered proteostasis or SG dynamics remain to be determined, the ability of TIA1 reduction to rescue the splicing dysfunction demonstrates the importance of RBP biology in the pathophysiology of tauopathies.

To further elucidate the global pathological impact of dysregulated RNA splicing in the context of PS19 tauopathy, we used an unbiased systems biology approach to gain broad insight into the mechanisms of neuroprotection afforded by TIA1 reduction. The NetDecoder analysis of the brain mRNA transcriptome in P301S Tia1+/− versus P301S Tia1+/- mice generated a list of key genes including network routers and key targets predicted to drive the neuroprotection associated with TIA1 reduction (Figure 5) (da Rocha et al., 2016). The NetDecoder-prioritized network indicates that PS3 and MYC operate in parallel pathways that act downstream of BRCA1 (Figure 5A). These genes are most classically associated with DNA damage (and caspase activity for PS3), but the pathway is notable for including SETX, which has mutations that are associated with motor neuron diseases (Chen et al., 2006; Couthouis et al., 2011, 2014). We also note that the expression of BRCA1 and Xist are inversely correlated in breast cancer cell lines, raising the possibility that changes in BRCA1 activity might underlie the increased Xist expression in the TIA1+/- cells (Sirchia et al., 2009). A recent study of immune cells also supports the role of TIA1 in regulating p33 and demonstrates that the regulation occurs post-transcriptionally (Diaz-Munoz et al., 2017). Targeting the EGFR is also of interest because the levels of EGFR transcript are altered in AD, suggesting involvement in the disease process (Conejero-Goldberg et al., 2011). Our experimental studies confirmed that inhibiting MYC or EGFR indeed resulted in protection against SG-mediated degeneration in tau-overexpressing primary neurons (Figure 6), suggesting a role for these pathways in the neurodegenerative process. The ability of these pathways to prevent stress-induced increases in TIA1 implicates regulation of TIA1 in the mechanisms of action (Figure 6). The lack of neuroprotective benefit observed with the UBE2I inhibitor might indicate that UBE2I is protective. Polymorphisms in the SUMO ligase UBE2I are genetically associated with AD in a Korean cohort, but studies suggest that sumoylation is protective in brain injury (Ahn et al., 2009; Yang et al., 2016). Thus, the upregulation of UBE2I in the PS19 mouse might be a compensatory response to the neurodegenerative changes or a tauopathy-independent effect of Tia1 heterozygosity.

This report demonstrates that tauopathy is associated with a profound dysregulation of RNA splicing. We also identify a number of candidate therapeutic targets that mediate the neuroprotective benefits associated with TIA1 reduction. The potential value of targeting RNA metabolism is highlighted by a recent study using a TDP-43 model of ALS, which demonstrated that reducing the RBP ataxin-2 also produced strong rescue of the disease phenotype (Becker et al., 2017). These studies present RBPs and RNA metabolism as powerful modulators of disease progression in both tauopathies and motor neuron disorders. This study also demonstrates that the effects of dysfunctional RNA splicing reach far from the soma, contributing to the dysfunctional neurotransmission that is associated with neural network dysfunction in tauopathies. Finally, deciphering context-specific information flows in a biological network using our unbiased systems biology approach reveals a wide range of therapeutic candidates for the treatment of tauopathies.

**STAR METHODS**

Detailed methods are provided in the online version of this paper and include the following:

- **KEY RESOURCES TABLE**
- **LEAD CONTACT AND MATERIALS AVAILABILITY**
- **EXPERIMENTAL DATA AND SUBJECT DETAILS**
  - In Vivo Animal Subjects
  - Human Subjects
  - Primary neuron cultures
  - SH-SYSY Cell Culture
  - Sex of Model Systems
- **METHOD DETAILS**
  - Genotyping
  - RNA-Seqencing and Analysis
  - Sequence Alignment
  - Quantitative RT-PCR
  - Context-Dependent Network Analysis Using NetDecoder
  - Cell Culture
- **QUANTIFICATION AND STATISTICAL ANALYSIS**
- **DATA AND SOFTWARE AVAILABILITY**

**SUPPLEMENTAL INFORMATION**

Supplemental Information can be found online at https://doi.org/10.1016/j.celrep.2019.11.093.

**ACKNOWLEDGMENTS**

We gratefully acknowledge receiving brain tissues from the Boston University ADC Brain Bank (AG013848) and the Harvard Brain Tissue Resource Center.
Funding was provided by the following agencies and foundations: for B.W., NIH-NIEHS (ES020395), NINDS (NS089544), NIA (AG050471, AG056318, and AG061706), the Alzheimer Association, BrightFocus Foundation, and the CureAlzheimer Foundation; and for H.L., NIA (CA196631 and AG056318), the Glenn Foundation for Medical Research, the Mayo Clinic Center for Biomedical Discovery, the Mayo Clinic Cancer Center, and the Margaret T. Grohne Cancer Immunology and Immunotherapy Program.

AUTHOR CONTRIBUTIONS

D.J.A. and C.Z. designed, performed, and analyzed experiments and helped to write and edit the manuscript; B.M. and L.J. designed and performed experiments; S.B. performed experiments; H.I.B. and C.U. contributed to experimental analysis; and H.L. and B.W. conceived of the project, designed experiments, analyzed experiments, and helped to write and edit the manuscript.

DECLARATION OF INTERESTS

B.W. is co-founder and chief scientific officer of Aquinnah Pharmaceuticals Inc. D.J.A. is now an employee of Biogen Inc. The other authors declare no competing interests.

Received: December 3, 2018
Revised: May 28, 2019
Accepted: November 22, 2019
Published: December 24, 2019

REFERENCES

Ahn, K., Song, J.H., Kim, D.K., Park, M.H., Jo, S.A., and Koh, Y.H. (2009). Ubc9 gene polymorphisms and late-onset Alzheimer’s disease in the Korean population: a genetic association study. Neurosci. Lett. 465, 272–275.
Amador-Ortiz, C., Lin, W.L., Ahmed, Z., Personett, D., Davies, P., Duara, R., Graft-Radford, N.R., Hutton, M.L., and Dickson, D.W. (2007). TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer’s disease. Ann. Neurol. 61, 435–445.
Anderson, P., and Kedersha, N. (2008). Stress granules: the Tao of RNA triage. Trends Biochem. Sci. 33, 141–150.
Apicco, D., Ash, P., Maziuk, B., LeBlang, C., Medalla, M., Al Abdullatif, A., Ferragud Faus, A., Botelho, E., Ballance, H., Dhanv, U., et al. (2018). Reducing the RNA binding protein TIA1 protects against tau-mediated neurodegeneration in vivo. Nat. Neurosci. 21, 72–80.
Arai, T., Mackenzie, I.R., Hasegawa, M., Nonoka, T., Niizato, K., Tsuichia, K., Iritani, S., Onaya, M., and Akiyama, H. (2009). Phosphorylated TDP-43 in Alzheimer’s disease and dementia with Lewy bodies. Acta Neuropathol. 117, 125–136.
Bai, B., Hales, C.M., Chen, P.C., Gozal, Y., Dammer, E.B., Fritz, J.J., Wang, X., Xia, Q., Duong, D.M., Street, C., et al. (2013). U1 small nuclear ribonucleoprotein complex and RNA splicing alterations in Alzheimer’s disease. Proc. Natl. Acad. Sci. USA 110, 16562–16567.
Barbash, S., Garfinkel, B.P., Mazo, R., Simchovitz, A., Nadorp, B., Guffanti, A., Bennett, E.R., Nadeau, C., Turk, A., Paul, L., et al. (2017). Alzheimer’s brains show inter-related changes in RNA and lipid metabolism. Neurobiol. Dis. 106, 1–13.
Becker, L.A., Huang, B., Bieri, G., Ma, R., Knowles, D.A., Jafar-Nejad, P., Messing, J., Kim, H.J., Soriano, A., Auburger, G., et al. (2017). Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. Nature 544, 367–371.
Bigio, E.H., Mishra, M., Hatanpaa, K.J., White, C.L., 3rd, Johnson, N., Rade-maker, A., Weitner, B.B., Deng, H.X., Dubner, S.D., Weintrab, S., and Mesulam, M. (2010). TDP-43 pathology in primary progressive aphasia and frontotemporal dementia with pathologic Alzheimer disease. Acta Neuropathol. 120, 43–54.
Blake, J.A., Eppig, J.T., Kadin, J.A., Richardson, J.E., Smith, C.L., and Bult, C.J.; the Mouse Genome Database Group (2017). Mouse Genome Database (MGD)-2017: community knowledge resource for the laboratory mouse. Nucleic Acids Res. 45 (D1), D723–D729.
Brunello, C.A., Yan, X., and Huttunen, H.J. (2016). Internalized Tau sensitizes cells to stress by promoting formation and stability of stress granules. Sci. Rep. 6, 30498.
Chen, Y.Z., Bennett, C.L., Huynh, H.M., Blair, I.P., Puis, I., Irobi, J., Dierick, I., Abel, A., Kennerson, M.L., Rabin, B.A., et al. (2004). DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4). Am. J. Hum. Genet. 74, 1128–1135.
Chen, Y.Z., Hashemi, S.H., Anderson, S.K., Huang, Y., Moreira, M.C., Lynch, D.R., Glass, I.A., Chance, P.F., and Bennett, C.L. (2006). Senataxin, the yeast Sen1p ortholog: characterization of a unique protein in which recessive mutations cause ataxia and dominant mutations cause motor neuron disease. Neurobiol. Dis. 23, 97–108.
Cline, M.S., Smoot, M., Cerami, E., Kuchinsky, A., Landys, N., Workman, C., Christmas, R., Avila-Campilo, I., Creech, M., Gross, B., et al. (2007). Integration of biological networks and gene expression data using Cytoscape. Nat. Protoc. 2, 2986–2989.
Conejero-Goldberg, C., Hyde, T.M., Chen, S., Drees-Werrinloer, U., Herman, M.M., Kleinman, J.E., Davies, P., and Goldberg, T.E. (2011). Molecular signatures in post-mortem brain tissue of younger individuals at high risk for Alzheimer’s disease as based on APOE genotype. Mol. Psychiatry 16, 836–847.
Couthouis, J., Hart, M.P., Shorter, J., DeJesus-Hernandez, M., Erion, R., Oris-tano, R., Liu, A.X., Ramos, D., Jethava, N., Hosangadi, D., et al. (2011). A yeast functional screen predicts new candidate ALS disease genes. Proc. Natl. Acad. Sci. USA 108, 20881–20890.
Couthouis, J., Raphael, A.R., Daneshjou, R., and Gitter, A.D. (2014). Targeted exon capture and sequencing in sporadic amyotrophic lateral sclerosis. PLoS Genet. 10, e1004704.
da Rocha, E.L., Ung, C.Y., McGehee, C.D., Correia, C., and Li, H. (2016). Net-Decoder: a network biology platform that decodes context-specific biological networks and gene activities. Nucleic Acids Res. 44, e100.
Diaz-Munoz, M.D., Kiselev, V.Y., Leone` re, N., Curk, T., and Turner, D.R., Glass, I.A., Chance, P.F., and Bennett, C.L. (2006). Senataxin, the yeast Sen1p ortholog: characterization of a unique protein in which recessive mutations cause ataxia and dominant mutations cause motor neuron disease. Neurobiol. Dis. 23, 97–108.
Feric, M., Vaidya, N., Harmon, T.S., Mitrea, D.M., Zhu, L., Richardson, T.M., Krivacki, R.W., Pappu, R.V., and Brangwynne, C.P. (2016). Coexisting Liquid Phases Underlie Nucleolar Subcompartments. Cell 165, 1666–1697.
Fernández-Nogales, M., Cabrera, J.R., Santos-Galindo, M., Hoozemans, J.J., Ferrer, I., Rozemuller, A.J., Hernández, F., Avila, J., and Lucas, J.J. (2014). Huntington’s disease is a four-repeat tauopathy with tau nuclear rods. Nat. Med. 20, 881–885.
Finelli, M.J., Liu, K.X., Wu, Y., Oliver, P.L., and Davies, K.E. (2015). Oxt1 im-proves pathogenic cellular features of ALS-associated FUS and TDP-43 mutations. Hum. Mol. Genet. 24, 3529–3544.
Fujitaka, S., Suzuki, K., Takahashi, H., Arai, T., Nonaka, T., Niizato, K., Tsuichia, K., Iritani, S., Onaya, M., and Akiyama, H. (2009). Phosphorylated TDP-43 in Alzheimer’s disease and dementia with Lewy bodies. Acta Neuropathol. 117, 125–136.
Gamir-Morralla, A., Bebin, O., Fortea, J., Alcolea, D., Ferrer, I., Lieó, A., and Iglesias, T. (2017). Kidins220 Correlates with Tau in Alzheimer’s Disease Brain and Cerebral Spinal Fluid. J. Alzheimers Dis. 55, 1327–1333.
Guo, C., Yeung, H.H., Hsieh, Y.C., Klein, H.U., Bennett, D.A., De Jager, P.L., Liu, Z., and Shulman, J.M. (2018). Tau Activates Transposable Elements in Alzheimer’s disease. Cell Rep. 23, 2874–2880.
Hackman, P., Sarparanta, J., Lehtinen, S., Vihola, A., Evila, A., Jonson, P.H., Luque, H., Kere, J., Screen, M., Chinnery, P.F., et al. (2013). Welander distal myopathy is caused by a mutation in the RNA-binding protein TIA1. Ann. Neu-rol. 73, 500–509.
Hanger, D.P., Byers, H.L., Wray, S., Leung, K.Y., Saxton, M.J., Seereeram, A., Reynolds, C.H., Ward, M.A., and Anderton, B.H. (2007). Novel phosphorylation
sites in tau from Alzheimer brain support a role for casexin kinase 1 in disease pathogenesis. J. Biol. Chem. 282, 23645–23654.
Hsieh, Y.C., Guo, C., Yalamanchili, H.K., Abreha, M., Al-Duran, R., Li, Y., Dammer, E.B., Lah, J.J., Levey, A.I., Bennett, D.A., et al. (2019). Tau-Mediated Disruption of the Spliceosome Triggers Cryptic RNA Splicing and Neurodegeneration in Alzheimer’s Disease. Cell Rep. 29, 301–316.e10.
Huang da, W., Sherman, B.T., and Lempicki, R.A. (2009). Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44–57.
Kim, D., Pertea, G., Trapnell, C., Pimentel, H., Kelley, R., and Salzberg, S.L. (2013). TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 14, R36.
Klein, C., Pramstaller, P.P., K., B., Page, C.C., Kann, M., Leung, J., Woodward, H., Castellan, C.C., Scherer, M., Vieregge, P., et al. (2000). Parkin deletions in a family with adult-onset, tremor-dominant parkinsonism: expanding the phenotype. Ann. Neurol. 48, 65–71.
Kohli, M.A., Cukier, H.N., Hamilton-Nelson, K.L., Rolati, S., Kunkle, B.W., Whitehead, P.L., Züchner, S.L., Farrer, L.A., Martin, E.R., Beecham, G.W., et al. (2016). Segregation of a rare TTC3 variant in an extended family with late-onset Alzheimer disease. Neurol. Genet. 2, e41.
Koike, M., Tsukada, S., Tsuzuki, K., Kijima, H., and Ozawa, S. (2000). Regulation of kinetic properties of GluR2 AMPA receptor channels by alternative splicing. J. Neurosci. 20, 2168–2174.
Kwiatkowski, T.J., Jr., Bosco, D.A., Leclerc, A.L., Tamrazian, E., Vanderburg, C.R., Russ, C., Davis, A., Gilchrist, J., Kasarskis, E.J., Munisat, T., et al. (2009). Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 323, 1205–1206.
Langmead, B., Trapnell, C., Pop, M., and Salzberg, S.L. (2009). Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 10, R25.
Li, P., Banjade, S., Cheng, H.C., Kim, S., Shen, B., Guo, L., Liaguno, M., Hollingsworth, J.V., King, D.S., Banani, S.F., et al. (2012). Phase transitions in the assembly of multivalent signalling proteins. Nature 483, 336–340.
Li, W., Huang, Z., Han, Y., Park, J.S., and Niu, L. (2009). Flip and flop: a molecular determinant for AMPA receptor channel opening. Biochemistry 48, 3768–3777.
Phillips, K., Kedersen, N., Shen, L., Blackshear, P.J., and Anderson, P. (2004). Arthritis suppressor genes TIA-1 and TTP dampen the expression of tumor necrosis factor alpha, cyclooxygenase 2, and inflammatory arthritis. Proc. Natl. Acad. Sci. USA 101, 2011–2016.
Prudencio, M., Beilz, V.V., Batra, R., Ross, C.A., Gendron, T.F., Pregent, L.J., Murray, M.E., Overstreet, K.K., Piazza-Johnston, A.E., Desaro, P., et al. (2015). Distinct brain transcriptome profiles in C9orf72-associated and sporadic ALS. Nat. Neurosci. 18, 1175–1182.
Selkoe, D.J., and Schenk, D. (2003). Alzheimer’s disease: molecular understanding predicts amyloid-based therapeutics. Annu. Rev. Pharmacol. Toxicol. 43, 545–584.
Sirchia, S.M., Tabano, S., Monti, L., Recalcati, M.P., Gariboldi, M., Grati, F.R., Porta, G., Finelli, P., Radice, P., and Miozzo, M. (2009). Misbehaviour of XIST RNA in breast cancer cells. PLoS ONE 4, e5559.
Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., and Mesirov, J.P. (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15445–15505.
Taylor, J.P., Brown, R.H., Jr., and Cleveland, D.W. (2016). Decoding ALS: from genes to mechanism. Nature 539, 197–206.
Trapnell, C., Roberts, A., Goff, L., Pertea, G., Kim, D., Kelley, D.R., Pimentel, H., Salzberg, S.L., Rinn, J.L., and Pachter, L. (2012). Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat. Protoc. 7, 562–578.
Um, J.W., Nyaegaard, H.B., Heiss, J.K., Kostylev, M.A., Stagi, M., Vortmeyer, A.O., Wieniaewski, T., Gunter, E.C., and Strittmatter, S.M. (2012). Alzheimer amyloid-β oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat. Neurosci. 15, 1227–1235.
Vance, C., Rogelj, B., Hordt, T., De Vos, K.J., Nishimura, A.L., Sreedharan, J., Xu, H., Smith, B., Ruddy, D., Wright, P., et al. (2009). Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 2. Cell 138, 2018–2021.
Vanderweyde, T., Yu, H., Varam, M., Liu-Yesucevitz, L., Citro, A., Ikekuz, T., Duff, K., and Wolozin, B. (2012). Consistent pathology of the stress granule proteins TIA-1 and G3BP in taupathies. J. Neurosci. 32, 8270–8283.
Vanderweyde, T., Apicco, D.J., Youmans-Kidder, S., Ash, P.E.A., Cook, C., Lummertz da Rocha, E., Jansen-West, K., Frame, A.A., Citro, A., Leszyk, J.P., et al. (2016). Interaction of tau with the RNA-binding Protein TIA1 Regulates tau Phathophysiology and Toxicity. Cell Rep. 15, 1455–1466.
Wang, Z., Kayikci, M., Biese, M., Zarnack, K., Luscombe, N.M., Rot, G., Zupan, B., Curk, T., and Ule, J. (2010). iCLIP predicts the dual splicing effects of TIA-RNA interactions. PLoS Biol. 8, e1000330.
Wickham, H. (2009). ggplot2: Elegant Graphics for Data Analysis (Springer-Verlag).
Wu, J., Anczuków, O., Krainer, A.R., Zhang, M.Q., and Zhang, C. (2013). OLEgo: fast and sensitive mapping of spliced mRNA-Seq reads using small seeds. Nucleic Acids Res. 47, 5149–5163.

Yang, W., Sheng, H., and Wang, H. (2016). Targeting the SUMO pathway for neuroprotection in brain ischaemia. Stroke Vasc. Neurol. 1, 101–107.

Yoshiyama, Y., Higuchi, M., Zhang, B., Huang, S.M., Iwata, N., Saido, T.C., Maeda, J., Suhara, T., Trojanowski, J.Q., and Lee, V.M. (2007). Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53, 337–351.

Zempel, H., and Mandelkow, E. (2014). Lost after translation: missorting of Tau protein and consequences for Alzheimer disease. Trends Neurosci. 37, 721–732.

Zhang, Y., Liu, T., Meyer, C.A., Eeckhoute, J., Johnson, D.S., Bernstein, B.E., Nusbaum, C., Myers, R.M., Brown, M., Li, W., and Liu, X.S. (2008). Model-based analysis of ChIP-Seq (MACS). Genome Biol. 9, R137.
### STAR METHODS

#### KEY RESOURCES TABLE

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| **Chemicals, Peptides, and Recombinant Proteins** | | |
| MYC inhibitor (10058-F4) | Sigma | Cat# F3680 |
| UBE2I inhibitor (2-D08) | Sigma | Cat# SML1052 |
| EGFR inhibitor (Tyrophostin AG-1478) | Sigma | Cat# T4182 |
| **Critical Commercial Assays** | | |
| Casp 3/7 Glo caspase activation kit | Promega | G8093 |
| XTT assay | Sigma-Aldrich | |
| iQ SYBR Green Supermix | BioRad | Cat# 1708880 |
| High-Capacity cDNA Reverse Transcription Kit | Applied Biosystems | Cat# 4368814 |
| TruSeq Stranded Total Sample Preparation kit | Illumina | Cat# 20020596 |
| RNeasy Mini kit | QIAGEN | Cat# 73404 |
| **Deposited Data** | | |
| RNA-seq data | GEO | GSE109226 |
| **Experimental Models: Organisms/Strains** | | |
| PS19 mice | The Jackson Laboratory | Stock #008169 RRID: IMSR_JAX:008169 |
| C57BL/6J mice | The Jackson Laboratory | Stock #000664 RRID: IMSR_JAX:000664 |
| B6.129S2(C)-Tia1tm1Andp/J | Anderson Laboratory | RRID: MGI:3037319 |
| **Software and Algorithms** | | |
| Tophat 2.0.12 | Kim et al., 2013 | http://ccb.jhu.edu/software/tophat/ |
| featureCounts v1.4.6-p2 | Liao et al., 2014 | http://subread.sourceforge.net/ |
| DESeq2 | Love et al., 2014 | https://bioconductor.org/packages/release/bioc/html/DESeq2.html |
| Gene Set Enrichment Analysis | Subramanian et al., 2005 | http://software.broadinstitute.org/gsea/index.jsp |
| OLeGO | Wu et al., 2013 | https://zhanglab.c2b2.columbia.edu/index.php/OLeGO |
| Bowtie 1.1.0 | Langmead et al., 2009 | http://bowtie-bio.sourceforge.net/index.shtml |
| MACS 1.4.2 | Zhang et al., 2008 | http://liulab.dfci.harvard.edu/MACS/ |
| NetDecoder | da Rocha et al., 2016 | http://netdecorator.hms.harvard.edu/ |

#### LEAD CONTACT AND MATERIALS AVAILABILITY

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Benjamin Wolozin, M.D., Ph.D. (bwolozin@bu.edu). This study did not generate unique reagents.

#### EXPERIMENTAL MODEL AND SUBJECT DETAILS

**In Vivo Animal Subjects**

Tia1−/− mice (B6.129S2(C)-Tia1tm1Andp/J) were generated by Anderson and colleagues and obtained from Harvard University, Dana Farber Cancer Institute (Phillips et al., 2004); these mice have been backcrossed for 10+ generations to a 100% C57BL/6J genetic background. PS19 (B6;C3-Tg(MAPT*P301S)PS19Vle/J, stock #008169) and C57BL/6J (stock #000664) mice were purchased from The Jackson Laboratory (Yoshiyama et al., 2007). All animals were housed in IACUC-approved vivariums at Boston University School of Medicine. To generate colonies of P301S Tia1+/+ and P301S Tia1+/- mice, PS19 mice were bred with Tia1−/− mice to produce...
pups that were heterozygous for the endogenous mouse Tia1 allele (Tia1+/−) and either transgenic (P301S+/−, or ‘P301S Tau’) or non-transgenic (P301S−/−, or ‘WT Tau’) for human P301S Mapt. Transgenic (P301S+/− Tia1+/−) and non-transgenic (P301S−/− Tia1+/−) pups from the F1 generation were then bred to produce littermate control P301S Tia1+/+ and P301S Tia1+/- mice on identical genetic backgrounds, which were then used in the experiments described in this manuscript. Mice were aged to 9 months of age and euthanized for RNA extraction and cDNA library preparation, as described below. Only male mice were used in the analysis, except where noted otherwise. Mice that were displaying end-stage and/or neuromuscular symptoms of disease (postural instability, dragging of one or more hind limbs, or greater than 10 percent loss in body weight) were excluded from the RNA-seq analysis. Animals were assigned to experimental groups by genotyping, as described below. The animal care and use committee for Boston University Medical Center approved the animal protocols used in this manuscript.

**Human Subjects**
Data downloaded from the short read archive project SRP034831

**Primary neuron cultures**
Primary neurons used in these studies were generated from mixed sex neonatal C57BL/6J mouse pups. Pups were anesthetized, euthanized, and their hippocampi dissected in Hank’s Buffered Saline Solution (HBSS). Cells were plated in Poly-D-Lysine coated cell culture plates and maintained in Neuron Feeding Media (Neurobasal media supplemented with 1% penicillin- streptomycin, B-27, and L-Glutamine) for 14 to 21 days *in vitro* (DIV). Neuron viability was then analyzed by the methods described below.

**SH-SY5Y Cell Culture**
SH-SY5Y cells were obtained from ATCC (CRL-2266) in DMEM/F12 medium with 10%FBS. SH-SY5Y cells were originally derived from a human female.

**Sex of Model Systems**
- P301S Mapt mice were male, unless otherwise noted
- Primary neuronal cultures were mixed sex
- SH-SY5Y cells are female

**METHOD DETAILS**

**Genotyping**
Tail snips from ear tagged mice were digested using Proteinase K, and the DNA was purified using the QIAGEN DNeasy kit according to manufacturer’s instructions (cat# 69504). The human 1N4R P301S transgene was amplified using the following primers (hTau Forward = GGG GAC ACG TCT CCA CGG CAT CTC AGC AAT GTC TCC; hTau Reverse = TCC CCC AGC CTA GAC CAC GAG AAC AT) using the cycling parameters specified by The Jackson Laboratory ([https://www.jax.org/strain/008169 CODE:25939,008169](https://www.jax.org/strain/008169 CODE:25939,008169)). Mice were also genotyped for both the wild-type Tia1 allele (WT mTia1 Forward = CTC CTT TAC CAG GAC CAC CA; WT mTia1 Reverse = ACC ATG GGG AAA AGG AGG TA) and frame shifted mutant allele that does not encode TIA1 protein (Mutant mTia1 Forward = CTC CTT TAC CAG GAC CAC CA; Mutant mTia1 Reverse = GCC AGA GGC CAC TTG TGT AG), also using the cycling parameters specified by The Jackson Laboratory ([https://www.jax.org/strain/009248 CODE:23469,009248](https://www.jax.org/strain/009248 CODE:23469,009248)). Amplified DNA was separated by electrophoresis in a 2% agarose gel, and visualized with 1% ethidium bromide using a BioRad imager.

**RNA-Sequencing and Analysis**
Total brain (cortex) RNA extracts were purified according to manufacturer’s instruction using the QIAGEN DNeasy kit according to manufacturer’s instructions (cat# 79306) and RNeasy Mini kit (Cat# 73404). The quality of the RNA preparations was confirmed using an Agilent bioanalyzer instrument (RIN scores > 9.0). A total of 100 ng of RNA in a 5 µl volume was used for library preparation and RNA-Seq (n = 3/genotype). Paired-end sequencing libraries were prepared by the Mayo Clinic sequencing core facilities (Rochester, MN) with the TruSeq Stranded Total Sample Preparation kit (Illumina), after which samples were subjected to quality control, cluster generation, and sequencing at a read depth of 60 million reads per sample on the Illumina HiSeq 2000 platform. The reads were de-multiplexed and converted to FASTQ format using CASAVA software from Illumina (by the Mayo Clinical core). All RNA-Seq data for each individual RNA sample are available at the NCBI Gene Expression Omnibus under a unique accession number (to be provided upon acceptance of the manuscript).

**Sequence Alignment**
Sequence alignment was performed using Bowtie and TopHat v2.0.12 programs against the UCSC mm10 Assembly ([Kim et al., 2013](https://www.jax.org/strain/008169 CODE:25939,008169)). Expression values were calculated with featureCounts v1.4.6-p2, and differential expression analysis was done using DESeq2 ([Love et al., 2014](https://www.jax.org/strain/009248 CODE:23469,009248)), and the volcano plots were made in R (v3.1.1; [http://www.r-project.org/](http://www.r-project.org/)) ([Langmead et al., 2009](https://www.jax.org/strain/008169 CODE:25939,008169); [Liao et al., 2014](https://www.jax.org/strain/009248 CODE:23469,009248); [Trapnell et al., 2012](https://www.jax.org/strain/008169 CODE:25939,008169)). Gene Set Enrichment Analysis (GSEA) was performed as described previously ([Subramanian et al., 2005](https://www.jax.org/strain/008169 CODE:25939,008169)).
Splicing analysis: Quantification of alternative splicing (AS) events were done separately using OLego, a seed-and-end aligner that has high sensitivity for splice-junction mapping of very small seeds (14-nt seed size) (Wu et al., 2013). After alignment using OLego, we determined and quantified differential cassette exon events using the Quantas module, as described in OLego, and used Fisher’s exact test to evaluate the statistical significance of splicing changes. For analysis of iCLIP data for human TIA1 (Wang et al., 2010), reads were mapped to reference genome UCSC hg19 using Bowtie v1.1.0 after removing barcodes and then peaks were called using MACS v1.4.2 (Langmead et al., 2009; Zhang et al., 2008).

**Quantitative RT-PCR**

Total brain (cortex) RNA extracts purified as described above were reverse-transcribed using the Applied Biosystems High-Capacity cDNA Reverse Transcription Kit according to manufacturer’s instruction (Cat# 4368814). RT-PCR reactions were performed in triplicate in a 384-well plate using 1 ng cDNA template, 200 nM forward and reverse primers, and 2x IQ SYBR Green Supermix (BioRad, Cat# #1708880) per well. Primer pairs for splice isoforms were designed to span exon-junctions of alternative splicing events. RT-PCR reactions were performed on a 7900HT Fast Real-Time PCR System (Applied Biosystems). The primers used were the following: Gria2_total_forward, GTGTTTATGGTGATGAGC; Gria2_total_reverse, TTTCAGCAGAGATCCAG; Gria2_Ex14_Flip_forward, GTCGTACCACCATTTGTTT; Gria2_Ex15_Flop_forward, GTCCACAATGAATGAGTACA; Gria2_Ex15_Flop_reverse, GCACGGTGTCCCTCTTAAT; Snap25_total_forward, TGTGTTAGTGATGAGC; Snap25_total_reverse, AGAACCTTGTCTTCCCG; Snap25_Ex5_Incl_forward, AAGAAGGATGAAGCGATACCTAC; Snap25_Ex5_Incl_reverse, ACAAGGACATA TGAAGAGGC; Snap25_Ex6_Incl_forward, TTTGTTTATGGTGATGAGC; Snap25_Ex6_Incl_reverse, ATCCTGATTATGCCCCAG; Camk2b_total_forward, GTATGAGCGAGAGATCATTA; Camk2b_total_reverse, AGCTTCTCTCTCACCTTTT; Camk2b_Ex13_Skip_forward, TGGTTTATGGTGATGAGC; Camk2b_Ex13_Skip_reverse, TGATGGGCTGAGAAATTCT; Camk2b_Ex13_Incl_forward, GAAAGCAGATGAGCTCAAG; Camk2b_Ex13_Incl_reverse, CTCATATGTTGTGTTGTT; Gapdh_total_forward, TGGCTCAGATATCCTA GTAT; and Gapdh_total_reverse, GATGACAAGCTTCCCATTC. The relative amounts of each transcript, including splice isoforms, were calculated by normalizing the Ct scores to a reference transcript (ΔCtGapdh). Alternative splice isoforms were then further normalized to the total transcript level detected in the sample. The ratio of exon inclusion was then determined to be [(Isoform 1 CtGapdh)/ (Total ΔCtGapdh)] / [(Isoform 2 ΔCtGapdh) / (Total ΔCtGapdh)]. Since the raw Ct counts better reflect the amplification efficiency of each primer pair than the true expression levels of each splice isoform, we normalized the relative exon inclusion ratios in each genotype to WT level = 1. Thus, the values reported in the alternative splicing figures accurately reflect the relative changes in exon inclusion between groups, but not necessarily their true physiological levels in each genotype. RT-PCR reactions were performed using 3 male and 3 female tissues per genotype (n = 6/group) to control for sex differences in alternative splicing events and transcript expression.

**Context-Dependent Network Analysis Using NetDecoder**

NetDecoder is a network biology platform which uses process-guided flow algorithm to model context-specific information flows based on interactions between genes at protein level for a given biological state and perform differential network analysis between a pair of biological phenotypes (da Rocha et al., 2016). In current study, pair of interested phenotypes to compare is PS19 P301S Tia1 ± versus PS19 P301S Tia1 +/+, where context-dependent weighted interactions for each phenotype, source genes and targets genes were generated as below.

Context-dependent weighted interactome: Raw gene counts were normalized using DESeq2 (Love et al., 2014) and then mapped to their human homolog using the Mouse Genome Informatics database (Blake et al., 2017). Pearson’s coefficients of gene expression values were calculated across samples within each of the PS19 P301S Tia1 ± and PS19 P301S Tia1 +/+ groups for pairwise gene interactions available in a comprehensive pairwise protein-protein interaction (PPI) network, as described in da Rocha et al. (2016). The absolute values of the Pearson’s coefficients were used as weights of the PPI interaction network, forming context-specific weighted interactomes for each group. The Pearson’s coefficients were then used to define edge capacity and cost for flow calculation.

Source genes: These are genes where flows begin. Because we are interested in gene candidates that might offer neuroprotection in P301S Tia1 ± mice, the source genes were identified using a template-matching approach (Pavlidis and Noble, 2001) to select genes which are highly expressed in PS19 P301S Tia1 ± group but low in PS19 P301S Tia1 +/+ group. Genes were ranked by template-matching score in descending order and top 0.5% of the genes were selected as source genes.

Target genes: These are genes where flows end. The target genes were defined as transcriptional regulators based on GO annotations, i.e., genes of GO:0030676 (nucleic acid binding), GO:0006355 (regulation of transcription, DNA-templated) and GO:0008134 (transcription factor binding).

With the above setup and data preparation, NetDecoder was then used to find subnetworks with maximum flow from source to target genes mediated via GO annotations in each gene in the PPI network through the context-specific weighted interactomes for P301S Tia1 ± and PS19 P301S Tia1 +/+ groups respectively. More detailed description of process-guided flow algorithm can be found in da Rocha et al. (2016). By comparing the resulting flow profiles in PS19 P301S Tia1 ± and PS19 P301S Tia1 +/+ subnetworks, genes with large flow difference in the 2 flow subnetworks were identified as network routers when they were intermediary nodes in the context-specific weighted interactome and as key targets when they were target nodes. High impact score, which was a scoring scheme taking into consideration flow differences, establishment of new flows and change of sign of gene expression correlations (i.e., from positive Pearson correlation coefficient to negative coefficient or vice versa), were used to rank the genes and
identify high impact genes. Prioritized subnetwork (Figure 5A), which was a collection of flow paths with at least any 2 categories of genes out of network routers, key targets and high impact genes, was established by comparing the 2 flow subnetworks. Heatmaps of high impact genes, network routers and key targets (Figures 5B–5D) as well as bar charts for edges with large flow differences (Figure 5E) were plotted using the ggplot2 package (Wickham, 2009) in R. The prioritized subnetwork was visualized using Cytoscape (Cline et al., 2007).

**Cell Culture**

Hippocampi from neonatal C57BL/6J mice were dissected in HBSS, triturated, and cultured for 21 days in vitro (DIV), as described previously (Vanderweyde et al., 2016). Cells were plated in either 96-well plates (5,000 neurons/well; for caspase activation assay) or 12 mm glass coverslips previously coated with 100 ng/ml Poly-D-Lysine. Neurons were maintained in neuronal feeding media (Neurobasal media supplemented with 1% penicillin-streptomycin, B-27, and L-Glutamine), which was replaced with 1/3 volume per well twice per week (every 3-4 days). On DIV 2, neurons were transduced with AAVs (serotype 1, generously provided by the laboratory of Dr. Leonard Pettrucelli) expressing WT 0N4R human Tau (WT Tau AAV1), or vector control (Ctrl AAV1) at a multiplicity of infection (MOI) of 200. On DIV 14, neurons were treated with chemical inhibitors to MYC (5 μM 10058-F4, cat# F3680, Sigma), UBE2I (5μM 2-D08, cat# SML1052, Sigma), or EGFR (5 μM, Tyrphostin AG-1478, cat#T4182, Sigma) for 48 h. Then the cells were treated with inhibitor for 1hr, then sodium arsenite (125 μM, final concentration) was added. After 12 more hours, XTT reagent was added and viability measured after 4 hr. The experiments were done in a similar manner for the caspase activity assays, except that arsenite was not added; caspase activity was measured with the Casp 3/7 Glo caspase activation kit (Promega) on DIV 21. For immunocytochemistry experiments, SH-SY5Y cells were treated with each inhibitor (doses of 1 or 10 μM) for 30 min, then treated for 45 min with a combination of the inhibitor plus 0.5 mM arsenite. The cells were then fixed, and immunocytochemistry for TIA1 (anti-TIA1 antibody Abcam 40693, 1:200 dilution) was done.

**QUANTIFICATION AND STATISTICAL ANALYSIS**

Sequence alignment was performed using Bowtie and TopHat v2.0.12 programs against the UCSC mm10 Assembly (Kim et al., 2013). Expression values were calculated with feature Counts v1.4.6-p2, and differential expression analysis was done using DESeq2 (Love et al., 2014).

Splicing analysis: Quantification of alternative splicing (AS) events were done separately using OLego, a seed-and-extend aligner that has high sensitivity for splice-junction mapping of very small seeds (14-nt seed size) (Wu et al., 2013). After alignment using OLego, we determined and quantified differential cassette exon events using the Quantas module, as described in OLego, and used Fisher’s exact test to evaluate the statistical significance of splicing changes.

For all neuron culture and RT-PCR validation experiments, statistical analysis was performed using GraphPad Prism software. All statistical tests used, exact p values, and sample sizes are described in the figure legends.

**DATA AND SOFTWARE AVAILABILITY**

The RNaseq data have been deposited in the GEO under accession ID code GSE109226.
Dysregulation of RNA Splicing in Tauopathies

Daniel J. Apicco, Cheng Zhang, Brandon Maziuk, Lulu Jiang, Heather I. Ballance, Samantha Boudeau, Choong Ung, Hu Li, and Benjamin Wolozin
Supp. Fig. 1

50 genes with most significant FDR
size: 50
found: 50

Color Key

Row Z-Score

-2 -1 0 1 2

P301S-TIA1_het.1 P301S-TIA1_het.2 P301S-TIA1_het.3 P301S_1 P301S_2 P301S_3

+9.2159 311.0007F17Rik * +8.8575 Cxcl1 * +5.1265 Starg1t1 * +3.7776 Tmem40 * +3.6755 Fat322 * +3.5392 9300158H04Rik * +2.9431 Nlpc3-pc * +1.9705 Arfapt22 * +1.8714 Bene * +1.7302 Sox2ot * +1.7298 Ttx2 * +1.6813 Fub10 * +1.6034 Ifng2 * +1.4470 43035273F11Rik * +1.3173 Rpph11 * +1.3032 Mryn * +1.2755 Pochtag * +1.2749 A330050F15Rik * +1.1960 Fgf7 * +1.0708 Fndc5 * +1.0339 Gaim6 * +0.9966 Tinem260 * +0.9652 Popp * +0.9143 Ftx1 * +0.8199 Irs1 * +0.7565 C16orf4 * +0.6708 Eibi3a * +0.6607 Strada * +0.6388 Smn * +0.6022 Kdmda * +0.5410 Hif1an * +0.3763 Dmpc27 * +0.4063 Neo1 * +0.4364 Fstl1 * +0.4842 Disc1l1g1 * +0.4902 Nbk2 * +0.5466 Hes1h1 * +0.7341 Lcrl2 * +0.8560 Potm1 * +0.9165 Rsp220 * +1.0299 Rwrdi3 * +1.1347 Gmi5015 * +1.1495 Gmi3302 * +1.2013 Pkach * +1.6052 K15 * +1.8669 T30304J09Rik * +1.9805 Klam5d * +2.0336 Ddx5y * +2.1202 Erfi2dr2 * +4.2462 Uty *
Supplementary Figure 1 (related to Figures 2 and 3): HEAT map comparing gene expression of the PS19 P301S $Tia1^{+/+}$ vs PS19 P301S $Tia1^{+-}$ mice. Comparison of transcriptional profiles of 9-month P301S $Tia1^{+/+}$ and P301S $Tia1^{+-}$ mice. The transcripts with the 50 top FDR scores were selected for presentation. The corresponding data are listed in Supplemental Table 7.
Differential mRNA expression in TIA1+/- vs WT brain

Supp. Fig. 2

Ct Values for Sexually Dimorphic Genes in male WT and TIA1 +/- Brains
Supplementary Figure 2 (related to Figure 2): TIA1 heterozygosity regulates the expression of sexually dimorphic genes.  

**a.** Volcano plot of average mRNA transcript levels detected in the RNA-seq of 9-month Tia1+/- compared to WT cortex. Adjusted p values (y axis) were plotted against the log2-transformed fold change (x axis) in the average level of mRNA transcript in Tia1+/- and WT cortex (n=3/group). Note that mRNA transcript levels of sexually dimorphic genes are highly differentially expressed in Tia1+/- cortex.

**b.** Validation of change in expression levels for Xist, Ddx3y, and Eif2s3y in separate 6-month Tia1+/- and WT brain tissue (n=3 males per genotype). DDX3y, p=0.0019; eIF2s3y, p=0.0149; Xist, p=0.0093.
Supplementary Figure 3 (related to Figures 5 and 6): Disease phenotype in PS19 vs WT mice is regulated by a prioritized biological network. NetDecoder analysis was performed on the RNA-seq data from 9-month PS19 (P301S Tia1+/+) and WT cortex in order to identify context-dependent changes inherent to the disease phenotype in PS19 tauopathy mice, as described previously (Lummertz da Rocha et al., 2016). A. Prioritized network consisting of biological pathways predicted to regulate the differences in phenotype between PS19 and WT mice. Red and blue nodes denote proteins exhibiting either increased (red) or decreased (blue) information flow in PS19 compared to WT cortex. Arrows denote direction of information flow from source genes to target genes based on known protein-protein interaction (PPI) data. Network routers (diamonds) are upstream of intermediary (circles) and target (square) protein nodes. B-D. Key genes (B), network routers (C), and key targets (D) identified by NetDecoder analysis to mediate context-dependent disease phenotype in PS19 compared to WT cortex. E. Inhibition of MYC and UBE2I protects against tau toxicity. Primary hippocampal neurons from neonatal C57BL/6J mice were cultured for 21 days in vitro (DIV), and analyzed for caspase activation following 48 h treatment with vehicle control (Veh, DMSO) or a chemical inhibitor of MYC or UBE2I, using the Casp 3/7 Glo kit (Promega). The neurons were previously transduced on DIV 2 with AAVs (serotype 1, AAV1) expressing human WT Tau, human P301L Tau, or vector control (Ctrl). #p<0.1090 *p=0.0435 **p=0.0047 by 2-Way between-subjects ANOVA with Tukey’s post-hoc comparisons. Error bars denote means ± SEM (n=4/group).